Erez Israeli

We were also surprised by this. It was not part of any arrangement or anything like that. I cannot speak on the details on the relationship or the customers, but it's, it came from them, I guess, certain planning issues or mistake at their end and that's, the outcome of it.

Our list price will be, give or take about half of what Novo Nordisk will be, that's can be shared because it will be listed.

We are planning to maintain the base without Sema at around 20%. This is the plan, and the Sema is supposed to help us to get more than that.

Our underlying base business delivered overall a double-digit growth this quarter.

I still believe that if we will get the approval, we have a good chance to be alone or even with the low level of numbers of players that will compete.

You should assume that the old arrangement from Q4 is zero. Doesn't mean that it will not sell, but let's say just for another generic molecule.

I absolutely believe, and I'm maintaining it, that in the next two years, we will absolutely get back to the growth and to the margins.

The more Semaglutide we will have, the more growth we'll have, the more BD we'll have. We can actually do it much, much faster.

I'm not worried on the not getting approval. I'm certain that we'll get approval.

We are aiming that the base business will be always north of 50%. In Semaglutide, it should be even more than that on the gross margins and EBITDA, obviously, like always 25% or north of it.

The idea is between growing the base semaglutide and the expenses as well as a success BD, we will kind of manage to make sure that the growth is coming in the right way.

We are not desperate. We are actually very comfortable with what we do. We knew that Lina will come. No, we are not planning to cut expenses that are supporting the growth of the company.